PRINCETON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to announce its 2007 fourth quarter and year-end results on Tuesday, February 26, 2008 by press release after the financial markets close.
Following the release, Medarex's management will host a conference call and live webcast at 4:30 p.m. Eastern Time. To access the call live, please dial 1-866-510-0710 (U.S./Canada) or 1-617-597-5378 (international) and enter passcode number 15176024. The webcast can be accessed through the Investor Relations section of Medarex's website at http://www.medarex.com and will be archived for 14 days following the webcast.
A telephonic replay of the conference call will be available until midnight Eastern Time, March 4, 2008. Access numbers for this replay are 1-888-286-8010 (U.S./Canada) or 1-617-801-6888 (international); passcode number 75836084.
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over thirty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
|SOURCE Medarex, Inc.|
Copyright©2008 PR Newswire.
All rights reserved